These results were comparable with the results of in vitro tests using PC9 cells, a lung cancer cell line with an EGFR 19 deletion sensitive to EGFR-TKIs (standardized AUCs for gefitinib, afatinib, and osimertinib: −4.39, −3.15, and −3.21, respectively). This evidence concerns the gene EGFR and lung cancer.